Provided are CD19 binding molecules, including anti-CD19 antibodies, including antibody fragments such as single-chain fragments, and chimeric receptors including the antibodies, such as chimeric antigen receptors (CARs). Among the antibodies are human antibodies, including those that compete for binding to CD19 with reference antibodies, such as murine antibodies. In some embodiments, the antibodies display similar functional properties to the reference antibodies, such as comparable binding affinities and/or competitive inhibition properties. Also provided are genetically engineered cells expressing the chimeric receptors, and uses of the binding molecules and cells adoptive cell therapy.本發明提供CD19結合分子，包括抗CD19抗體，包括抗體片段，諸如單鏈片段；及包括該等抗體的嵌合受體，諸如嵌合抗原受體(CAR)。該等抗體為人類抗體，包括與參考抗體(諸如鼠類抗體)競爭結合至CD19的彼等物。在一些實施例中，該等抗體顯示與參考抗體類似的功能特性，諸如類似的結合親和力及/或競爭抑制特性。亦提供表現嵌合受體之經基因工程改造的細胞，及該等結合分子及細胞用於授受細胞療法的用途。
